세계 업스트림 바이오프로세스 시장(2023년-2030년)

Title: Global Upstream Bioprocessing Market Size, Share & Trends Analysis Report by Product (Bioreactors, Cell Culture Products, Filters, Bags and Containers and Others), by Workflow (Media Preparation, Cell Culture and Cell Separation), and by Use Type (Multi-Use and Single-Use),Forecast Period (2023-2030).

The global upstream bioprocessing market is anticipated to grow at a CAGR of 11.1% during the Forecast Period (2023-2030). An increase in advantage of automated upstream bioprocessing such as improved process control, enhanced product quality, reduced variability, increased throughput and efficiency, and cost savings drive the growth of market. The growing adoption of automated upstream bioprocessing with improved software is the key factor supporting the growth of the market globally. Capturing data directly at the bio production laboratory can help bioprocess engineers improve process understanding, leading to more robust manufacturing processes and accelerated development timelines. Various upstream bioreactors to automate routine product quality and cell culture media analyses. Hence, the market players are also focusing on launching automated Upstream Bioprocessing solutions that further bolster the market growth. For instance, in September 2023, Waters Corp. launched new bioprocess walk-up solutions designed to further simplify biologic sample prep and analysis. By eliminating the need to send bioreactor samples to a central laboratory for analysis, the new solutions make it even easier to accelerate upstream bioprocess. Waters OneLab™ laboratory automation software and new pre-developed analytical workflow allow bioprocess engineers to capture high-quality bioprocess

Segmental Outlook

The global upstream bioprocessing market is segmented on the product, workflow, and use type. Based on the product, the market is sub-segmented into bioreactors, cell culture products, filters, bags and containers and others (bioreactors accessories). Based on the workflow, the market is sub-segmented into media preparation, cell culture and cell separation. Further, on the basis of use type, the market is sub-segmented into multi-use and single-use. Among the workflow, the media preparation sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of specific media-formulated cell cultures that significantly impact mammalian cell growth and experimental outcomes. Culture media provide a source of energy for cell growth and compounds that regulate cellular processes.

The Cell Culture Products Sub-Segment is Anticipated to Hold a Considerable Share of the Global Upstream Bioprocessing Market

Among the products, the cell culture products sub-segment is expected to hold a considerable share of the global upstream bioprocessing market. The segmental growth is attributed to the growing influence of the development of cell lines in the lab that require a medium that supplies the nutrients necessary for cell cultures to survive and proliferate. The growth media also provides the correct osmolality and pH. The manufacture of CAR T-cells has traditionally relied on the use of animal or human serum, that is highly variable and may contain adventitious agents. Serum requires stringent safety testing, screening, and stockpiling of suitable-quality batches, making for a more costly and time-consuming manufacturing process. For instance, in May 2023, Lonza Group Ltd. launched the TheraPEAK® T-VIVO® Cell Culture Medium, a novel chemically defined medium developed to optimize CAR T-cell manufacture. Free from animal-origin components, the medium improves consistency and process control and simplifies regulatory approval for faster time-to-market.

Regional Outlook

The global Upstream Bioprocessing market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the rapid technological advancements and companies are constantly working towards the improvement of their products with a major focus on research and development. The key market players include BioSpectrum, Inc., Fujifilm Holdings Corp., Hash Biotech Labs, Samsung Biologics and others.

The North America Region is Expected to Grow at a Significant CAGR in the Global Upstream Bioprocessing Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the presence of major biopharmaceutical companies, increasing investment for research and development of new biomolecules & mAbs, increasing chronic disease burden, and the presence of developed infrastructure are major factors that drive the market growth in this region. Moreover, the development of automated bioreactors for safe, cost-effective, and regulatory-compliant manufacturing of cell-based products for clinical applications has driven the region's growth.

The market for upstream bioprocessing in the region is accelerated by an increase in research into the production of biosimilars/biomolecules, monoclonal antibodies, and tiny therapeutic peptides. The demand for process improvement and clean, secure, and effective biomolecule production fuels results in the market's expansion. Companies adopting patented cell lines result in a high success rate in the cell cultivation process and enable minimal regulatory risk and efficient commercial production. The key market player includes Corning Inc., Patheon N.V., PBS Biotech, Inc., Thermo Fisher Scientific, Inc. and others.

Market Players Outlook

The major companies serving the upstream bioprocessing market include: Corning, Inc., Eppendorf AG, Merck KGaA, Sartorius AG, Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, Cytiva and Culture Biosciences aims to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global upstream bioprocessing market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Corning, Inc.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
• 3.3. Sartorius AG
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Thermo Fisher Scientific Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Upstream Bioprocessing Market by Product
  • 4.1.1. Bioreactors
  • 4.1.2. Cell Culture Products
  • 4.1.3. Filters
  • 4.1.4. Bags and Containers
  • 4.1.5. Others (Bioreactors Accessories)
• 4.2. Global Upstream Bioprocessing Market by Workflow
  • 4.2.1. Media Preparation
  • 4.2.2. Cell Culture
  • 4.2.3. Cell Separation
• 4.3. Global Upstream Bioprocessing Market by Use Type
  • 4.3.1. Multi-Use
  • 4.3.2. Single-Use

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. AGC Inc.
• 6.2. Applikon Biotechnology
• 6.3. Bio-Connect Inc.
• 6.4. BioProcess International
• 6.5. Boehringer Ingelheim GmbH
• 6.6. CellGenix GmbH
• 6.7. Cytiva LifeScience
• 6.8. Danaher Corp.
• 6.9. Eppendorf AG
• 6.10. Esco Pharma
• 6.11. Getinge AB
• 6.12. Infors HT
• 6.13. Lonza Group Ltd.
• 6.14. Merck KGaA
• 6.15. Pall Corp.
• 6.16. PBS Biotech, Inc.
• 6.17. VWR International, LLC